Galmed says Aramchol oral film boosts bioavailability 150%, CNS exposure 300% in Parkinson’s program

• Galmed advanced Aramchol for Parkinson’s disease with an orally dispersible film formulation designed for buccal and sublingual absorption.
• Development data showed about 150% higher systemic bioavailability versus conventional oral dosing.
• CNS exposure increased about 300%, supporting a brain-targeted delivery strategy for its SCD1 inhibitor.
• Program positioned as a potential out-licensing candidate targeting a $6+ billion Parkinson’s therapeutics market.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Galmed Pharmaceuticals Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202607280700PR_NEWS_USPR_____IO13594) on July 28, 2026, and is solely responsible for the information contained therein.